Meeting
2019 ASCO Annual Meeting
Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma.
Authors
John Lin
Stanford University, Stanford, CA
John Lin , Lori S. Muffly , Michael Alexander Spinner , James I Barnes , Douglas K. Owens , Jeremy D Goldhaber-Fiebert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7561)
DOI
10.1200/JCO.2019.37.15_suppl.7561
Abstract #
7561
Poster Bd #
315
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.
First Author: Jonathan Bender
Poster
2020 ASCO Virtual Scientific Program
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
First Author: Frederick Lundry Locke
Poster
2023 ASCO Annual Meeting
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).
First Author: Ian W. Flinn
Poster
2023 ASCO Annual Meeting
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
First Author: Laura S. Samples